The "dark horse" variety of 278%of the skyrocketing, last year many companies have been commented!

Recently, the official website of the State Drug Administration (NMPA) released a new batch of drug approval documents.The hydrochloride atomization solution is an extension of the bronchial pipe and is used to treat or prevent bronchial spasm caused by adult and adult reversible airway obstructive diseases.According to, the hydrochloride atomization inhalation solution is amazing in the terminal of China's public medical institutions. In 2020, this variety is in Chinese urban public hospitals, county -level public hospitals, urban community centers, and township health centers Terminal sales are only 5 million yuan, and in 2021, it has soared to nearly 200 million yuan. In addition, according to the statistics of Yao Rongyun's data, in 2022, the market sales in my country's hospitals reached 678 million yuan, an increase of 278%year -on -year, a pair of "dark horse".

A $10 billion pesticide market, these blockbuster products support a world

Cereals are important food crops, including wheat, barley, rye, oats, durum wheat, millet, sorghum, triticale, etc., and are widely cultivated in most temperate regions. Grain is an important application field of pesticides, and it is also an important force to promote the innovation of pesticide products. The market for cereal pesticides is ahead of corn and rice, ranking first in the pesticide market for food crops. Among them, the market position of herbicides is the most important, accounting for more than half of the country, fungicides have 1/3 of the market share, and the weight of pesticides is low. In order to solve the new problems that continue to arise in grain production and ensure the healthy growth and bumper harvest of grain, the grain pesticide market has gathered a large number of R&D forces and promoted product iterative upgrading, among which there are many high-profile blockbuster new products. According to Phillips McDougall's forecast, the global cereal pesticide market is expected to exceed $10 billion in sales by 2024.

Ophthalmology sales volume NO.1 variety, sales rose 18.69% last year!

Age-related macular degeneration (AMD) is an important contributor to vision loss in elderly patients and is now the third leading cause of blindness worldwide after glaucoma and cataracts.AMD can be divided into two main types: a non-neovascularized, atrophic (dry) form and a neovascularized (wet) form ; and the majority of people with severe vision loss due to AMD have wet (wet) AMD (wAMD). Anti-VEGF ophthalmic drugs are the standard treatment for wAMD. Four anti-VEGF ophthalmic drugs, ranibizumab, abciximab, compazine and brolucizumab, are currently available worldwide, the first three of which have been approved for marketing in China.

Summary of drugs with expired patents in 2023

The expiration of drug patents has a great impact on the application and project establishment of generic drugs. Patent expiration means that drugs can be imitated. The expiration of the patent means that the safety and efficacy of the drug have been verified, and the registration application can refer to the research data of the original drug, the difficulty and risk of review are relatively small, and the probability of approval will be higher. Previously, 2-3 years after the expiration of the patent was the peak period for generic drug filings. Once the patent of the drug protected by the previous patent expires, the generic drug company will quickly start the research and development of the relevant drug and actively apply for marketing within 2-3 years after the patent expires. During this period, the number of generic drug declarations will increase significantly. However, if the research of generic drugs is completed before the patent expires and declared immediately after the patent expires, it has great advantages for generic drug companies to quickly occupy the market, and it is also necessary to select drugs with 2-3 years of patent expiration as the basis for generic drug projects, so it is necessary to monitor the situation of drug patents from time to time.

In 2023, 4 of the top 50 global pharmaceutical companies will be on the list

Recently, EvaluatePharma released the 2023 Global Pharmaceutical Top 50 ranking, of which Pfizer topped the list with $91.3 billion, and four pharmaceutical companies in China were on the list, namely: Pfizer, AbbVie, Johnson & Johnson, and Novartis. In addition, there are four pharmaceutical companies in China on the list, namely: China Biopharmaceutical, Shanghai Pharmaceutical, Jiangsu Hengrui Pharmaceutical, and CSPC Pharmaceutical Group. Merck's 2022 financial report showed growth in all business units, with global net income up 12.9% year-on-year to 22.2 billion euros ($23.6 billion).
< 123 >
Cooperation leads to bright future